Research programme: theta defensins - Oryn TherapeuticsAlternative Names: ORTD; ORTD-1; Orynotides; OTP-300; OTP-602
Latest Information Update: 07 Jul 2016
At a glance
- Originator Oryn Therapeutics
- Class Antibacterials; Antifungals; Antirheumatics; Macrocyclic compounds; Peptide antibiotics; Peptides
- Mechanism of Action Defensin modulators; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial infections; Rheumatoid arthritis
- Research Autoimmune disorders